

Dihua Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/589566/publications.pdf>

Version: 2024-02-01

166
papers

19,774
citations

13099

68
h-index

11607

135
g-index

172
all docs

172
docs citations

172
times ranked

24283
citing authors

#	ARTICLE	IF	CITATIONS
1	miR-7/TGF- β 2 axis sustains acidic tumor microenvironment-induced lung cancer metastasis. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 821-837.	12.0	15
2	The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. <i>Cancer Cell</i> , 2022, 40, 36-52.e9.	16.8	101
3	An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. <i>STAR Protocols</i> , 2022, 3, 101198.	1.2	2
4	Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. <i>Journal of Biological Chemistry</i> , 2022, 298, 101817.	3.4	15
5	Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. <i>Cancer Research</i> , 2022, 82, 2185-2195.	0.9	15
6	Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. <i>Cancer Discovery</i> , 2022, 12, 1742-1759.	9.4	35
7	EZH2 engages TGF- β 2 signaling to promote breast cancer bone metastasis via integrin β 1-FAK activation. <i>Nature Communications</i> , 2022, 13, 2543.	12.8	50
8	Tumor microenvironment as a therapeutic target in cancer. , 2021, 221, 107753.		567
9	Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. <i>Acta Neuropathologica</i> , 2021, 141, 303-321.	7.7	30
10	Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 832.	12.8	248
11	TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	135
12	Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. <i>Nature Communications</i> , 2021, 12, 2788.	12.8	11
13	Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. <i>Oncogene</i> , 2021, 40, 4992-5001.	5.9	68
14	Targeting the α v integrin/TGF- β 2 axis improves natural killer cell function against glioblastoma stem cells. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	117
15	Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. <i>American Journal of Cancer Research</i> , 2021, 11, 236-250.	1.4	2
16	Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 2005-2024.	1.4	1
17	Brain Metastasis Organotropism. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037242.	6.2	26
18	Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	64

#	ARTICLE	IF	CITATIONS
19	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. <i>Journal of Biomedical Science</i> , 2020, 27, 77.	7.0	89
20	EXTH-06. INTEGRATED MOLECULAR PROFILING REVEALS TARGETABLE MOLECULAR ABNORMALITIES SHARED ACROSS MULTIPLE HISTOLOGIES OF BRAIN METASTASIS. <i>Neuro-Oncology</i> , 2020, 22, ii87-ii88.	1.2	0
21	Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?. <i>Cell and Bioscience</i> , 2019, 9, 82.	4.8	6
22	Proteomics analysis of the matrisome from MC38 experimental mouse liver metastases. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G625-G639.	3.4	7
23	Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2019, 79, 4211-4226.	0.9	48
24	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. <i>Nature Immunology</i> , 2019, 20, 835-851.	14.5	277
25	The importance of developing therapies targeting the biological spectrum of metastatic disease. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 305-309.	3.3	9
26	Exosomes in cancer development, metastasis, and immunity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 455-468.	7.4	532
27	Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells. <i>Cancer Research</i> , 2018, 78, 2248-2261.	0.9	66
28	Working together to make AJCR stronger. <i>American Journal of Cancer Research</i> , 2018, 8, 1.	1.4	1
29	Brain metastasis: Unique challenges and open opportunities. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 49-57.	7.4	110
30	Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. <i>Cancer Research</i> , 2017, 77, 5374-5383.	0.9	118
31	Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. <i>Cancer Prevention Research</i> , 2017, 10, 641-650.	1.5	4
32	Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	12
33	14-3-3 loss leads to neonatal lethality by microRNA-126 downregulation-mediated developmental defects in lung vasculature. <i>Cell and Bioscience</i> , 2017, 7, 58.	4.8	7
34	Immunofluorescence. , 2017, , 135-150.		19
35	JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. <i>Journal of Clinical Investigation</i> , 2017, 127, 4498-4515.	8.2	177
36	Breast Cancer Multistep Development. , 2017, , 671-676.		0

#	ARTICLE	IF	CITATIONS
37	14-3-3 η loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling. <i>American Journal of Cancer Research</i> , 2017, 7, 1654-1664.	1.4	5
38	Upregulation of lactate dehydrogenase a by 14-3-3 η leads to increased glycolysis critical for breast cancer initiation and progression. <i>Oncotarget</i> , 2016, 7, 35270-35283.	1.8	27
39	Advances in decoding breast cancer brain metastasis. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 677-684.	5.9	7
40	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , 2016, 7, 12632.	12.8	648
41	Deubiquitination and Stabilization of PD-L1 by CSN5. <i>Cancer Cell</i> , 2016, 30, 925-939.	16.8	538
42	Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. <i>American Journal of Cancer Research</i> , 2016, 6, 981-95.	1.4	4
43	Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. <i>Stem Cells</i> , 2015, 33, 2985-2994.	3.2	45
44	Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. <i>World Journal of Clinical Oncology</i> , 2015, 6, 299.	2.3	31
45	14-3-3 η Turns TGF- β 's Function from Tumor Suppressor to Metastasis Promoter in Breast Cancer by Contextual Changes of Smad Partners from p53 to Gli2. <i>Cancer Cell</i> , 2015, 27, 177-192.	16.8	158
46	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. <i>Molecular Oncology</i> , 2015, 9, 586-600.	4.6	31
47	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. <i>Cancer Biology and Therapy</i> , 2015, 16, 402-411.	3.4	44
48	Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. <i>Cancer Research</i> , 2015, 75, 4863-4875.	0.9	44
49	Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. <i>Nature</i> , 2015, 527, 100-104.	27.8	966
50	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. <i>Oncotarget</i> , 2015, 6, 3932-3946.	1.8	60
51	Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. <i>American Journal of Cancer Research</i> , 2015, 5, 3624-34.	1.4	1
52	Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. <i>Cell Research</i> , 2014, 24, 542-559.	12.0	23
53	14-3-3 η Orchestrates Mammary Tumor Onset and Progression via miR-221-Mediated Cell Proliferation. <i>Cancer Research</i> , 2014, 74, 363-373.	0.9	28
54	MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. <i>Science Signaling</i> , 2014, 7, ra71.	3.6	90

#	ARTICLE	IF	CITATIONS
55	Enhanced PI3K p110 α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110 α -Selective PI3K Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 60-70.	4.1	34
56	Definition of PKC- δ , CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2014, 74, 4822-4835.	0.9	61
57	Cooperativity of Oncogenic K-Ras and Downregulated p16/INK4A in Human Pancreatic Tumorigenesis. <i>PLoS ONE</i> , 2014, 9, e101452.	2.5	39
58	Breast Cancer Multistep Development. , 2014, , 1-7.		0
59	S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 361-76.	0.0	32
60	Src Family Kinases as Novel Therapeutic Targets to Treat Breast Cancer Brain Metastases. <i>Cancer Research</i> , 2013, 73, 5764-5774.	0.9	108
61	Needle-based fluorescence endomicroscopy via structured illumination with a plastic, achromatic objective. <i>Journal of Biomedical Optics</i> , 2013, 18, 096003.	2.6	27
62	Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis. <i>PLoS ONE</i> , 2013, 8, e73406.	2.5	31
63	Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer. <i>Cancer Research</i> , 2012, 72, 4417-4428.	0.9	42
64	Overexpression of 14-3-3 σ in cancer cells activates PI3K via binding the p85 regulatory subunit. <i>Oncogene</i> , 2012, 31, 897-906.	5.9	92
65	Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 122-128.	8.7	254
66	The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis. <i>Cell</i> , 2012, 149, 1098-1111.	28.9	332
67	Growth factor signaling in metastasis: current understanding and future opportunities. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 479-491.	5.9	27
68	Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 487-498.	2.5	22
69	Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. <i>Breast Cancer Research</i> , 2012, 14, R4.	5.0	54
70	High-resolution Fiber-optic Microendoscopy for in situ Cellular Imaging. <i>Journal of Visualized Experiments</i> , 2011, , .	0.3	68
71	Cancer Cell Migration: Integrated Roles of Matrix Mechanics and Transforming Potential. <i>PLoS ONE</i> , 2011, 6, e20355.	2.5	42
72	p53 regulates epithelial \rightarrow mesenchymal transition and stem cell properties through modulating miRNAs. <i>Nature Cell Biology</i> , 2011, 13, 317-323.	10.3	674

#	ARTICLE	IF	CITATIONS
73	Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. <i>Nature Medicine</i> , 2011, 17, 461-469.	30.7	466
74	BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. <i>Cancer Cell</i> , 2011, 20, 341-356.	16.8	67
75	Microenvironment Determinants of Brain Metastasis. <i>Cell and Bioscience</i> , 2011, 1, 8.	4.8	36
76	Protein Microarray Analysis of Mammary Epithelial Cells from Obese and Nonobese Women at High Risk for Breast Cancer: Feasibility Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 476-482.	2.5	14
77	Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer. <i>Cancer Research</i> , 2011, 71, 603-613.	0.9	140
78	Nucleolin Protein Interacts with Microprocessor Complex to Affect Biogenesis of MicroRNAs 15a and 16*. <i>Journal of Biological Chemistry</i> , 2011, 286, 44095-44103.	3.4	62
79	Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 3126-3132.	1.6	207
80	Evidence That Aberrant Expression of Tissue Transglutaminase Promotes Stem Cell Characteristics in Mammary Epithelial Cells. <i>PLoS ONE</i> , 2011, 6, e20701.	2.5	56
81	Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 3126-3132.	1.6	10
82	TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. <i>Oncogene</i> , 2010, 29, 2047-2059.	5.9	173
83	Tissue Transglutaminase Promotes Drug Resistance and Invasion by Inducing Mesenchymal Transition in Mammary Epithelial Cells. <i>PLoS ONE</i> , 2010, 5, e13390.	2.5	110
84	Activation of Murine Double Minute 2 by Akt in Mammary Epithelium Delays Mammary Involution and Accelerates Mammary Tumorigenesis. <i>Cancer Research</i> , 2010, 70, 7684-7689.	0.9	17
85	PI(3)K Apart PTEN's Role in Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4325-4330.	7.0	221
86	Invasive breast cancer development: "Fatal accident" from malfunctions in both "motor" and "brake". <i>Cell Cycle</i> , 2010, 9, 421-422.	2.6	1
87	Cancer Cell Stiffness: Integrated Roles of Three-Dimensional Matrix Stiffness and Transforming Potential. <i>Biophysical Journal</i> , 2010, 99, 2048-2057.	0.5	137
88	PTEN, PIK3CA, p-AKT, and p-p70S6K Status. <i>American Journal of Pathology</i> , 2010, 177, 1647-1656.	3.8	276
89	Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 103-107.	2.1	30
90	14-3-3 σ as a prognostic marker and therapeutic target for cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1343-1354.	3.4	122

#	ARTICLE	IF	CITATIONS
91	Molecular predictors of response to trastuzumab and lapatinib in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 98-107.	27.6	148
92	Breast Cancer Metastasis: Challenges and Opportunities. <i>Cancer Research</i> , 2009, 69, 4951-4953.	0.9	202
93	14-3-3 η Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival. <i>Cancer Research</i> , 2009, 69, 3425-3432.	0.9	175
94	ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2009, 7, 592-600.	3.4	54
95	Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance. <i>Clinical Cancer Research</i> , 2009, 15, 1326-1334.	7.0	74
96	Upregulation of Neutrophil Gelatinase-Associated Lipocalin by ErbB2 through Nuclear Factor- κ B Activation. <i>Cancer Research</i> , 2009, 69, 9163-9168.	0.9	32
97	14-3-3 η Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition. <i>Cancer Cell</i> , 2009, 16, 195-207.	16.8	195
98	Oxygen sensor boosts growth factor signaling. <i>Nature Medicine</i> , 2009, 15, 246-247.	30.7	21
99	Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. <i>Oncogene</i> , 2009, 28, 3689-3701.	5.9	223
100	Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. <i>Oncogene</i> , 2009, 28, 2436-2445.	5.9	78
101	14-3-3 η/ζ , heterodimers regulate Slingshot activity in migrating keratinocytes. <i>Biochemical and Biophysical Research Communications</i> , 2009, 383, 450-454.	2.1	20
102	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. <i>Molecular Carcinogenesis</i> , 2008, 47, 701-706.	2.7	249
103	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. <i>Nature Cell Biology</i> , 2008, 10, 138-148.	10.3	590
104	14-3-3 η Down-regulates p53 in Mammary Epithelial Cells and Confers Luminal Filling. <i>Cancer Research</i> , 2008, 68, 1760-1767.	0.9	80
105	Ph.D. Training in Cancer Biology. <i>Cancer Research</i> , 2008, 68, 9122-9124.	0.9	6
106	The Impact of ErbB2 on Cancer Progression and Metastasis through Modulation of Tumor and Tumor Microenvironment. , 2008, , 43-56.		0
107	Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency. <i>Clinical Cancer Research</i> , 2007, 13, 5883-5888.	7.0	195
108	Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1650-1660.	4.1	116

#	ARTICLE	IF	CITATIONS
109	Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance. <i>Advances in Experimental Medicine and Biology</i> , 2007, 608, 119-129.	1.6	123
110	High prevalence of p53 exon 4 mutations in soft tissue sarcoma. <i>Cancer</i> , 2007, 109, 2323-2333.	4.1	39
111	Novel Approaches for Chemosensitization of Breast Cancer Cells: The E1A Story. <i>Advances in Experimental Medicine and Biology</i> , 2007, 608, 144-169.	1.6	21
112	Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 269-280.	4.3	858
113	Upregulation and activation of PKC ζ by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC ζ and Src inhibitors. <i>Oncogene</i> , 2006, 25, 3286-3295.	5.9	90
114	A license to kill: Adenoviral-vector based siRNA for mutant K-ras as a promising tool for lung cancer gene therapy. <i>Cancer Biology and Therapy</i> , 2006, 5, 1724-1725.	3.4	0
115	Dissection of Signaling Pathways in Fourteen Breast Cancer Cell Lines Using Reverse-Phase Protein Lysate Microarray. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 543-551.	1.9	21
116	Vascular Endothelial Growth Factor Overexpression by Soft Tissue Sarcoma Cells: Implications for Tumor Growth, Metastasis, and Chemoresistance. <i>Cancer Research</i> , 2006, 66, 8770-8778.	0.9	72
117	Synthetic triterpenoid 2-cyano-3,12-dioxoleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 317-328.	4.1	68
118	Selective Inhibition of ErbB2-Overexpressing Breast Cancer In vivo by a Novel TAT-Based ErbB2-Targeting Signal Transducers and Activators of Transcription 3 α "Blocking Peptide. <i>Cancer Research</i> , 2006, 66, 3764-3772.	0.9	118
119	Wild-type p53 Inhibits Nuclear Factor- κ B-Induced Matrix Metalloproteinase-9 Promoter Activation: Implications for Soft Tissue Sarcoma Growth and Metastasis. <i>Molecular Cancer Research</i> , 2006, 4, 803-810.	3.4	63
120	Prostate Tumor Cells Infected with a Recombinant Influenza Virus Expressing a Truncated NS1 Protein Activate Cytolytic CD8 + Cells To Recognize Noninfected Tumor Cells. <i>Journal of Virology</i> , 2006, 80, 383-394.	3.4	27
121	ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells. <i>Cancer Research</i> , 2006, 66, 2028-2037.	0.9	182
122	Mechanisms of Breast Cancer Resistance to Chemotherapy. , 2006, , 783-803.		0
123	A Novel Mechanism of Herceptin Resistance and Counteracting Strategies. <i>Journal of Immunotherapy</i> , 2005, 28, 652.	2.4	0
124	Mechanisms of Trastuzumab Resistance and Their Clinical Implications. <i>Annals of the New York Academy of Sciences</i> , 2005, 1059, 70-75.	3.8	68
125	A knotty turnabout?: Akt1 as a metastasis suppressor. <i>Cancer Cell</i> , 2005, 8, 437-439.	16.8	26
126	Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. <i>Cancer</i> , 2005, 103, 830-838.	4.1	81

#	ARTICLE	IF	CITATIONS
127	Transcriptional Repression of Protein Kinase C δ via Sp1 by Wild Type p53 Is Involved in Inhibition of Multidrug Resistance 1 P-Glycoprotein Phosphorylation. <i>Journal of Biological Chemistry</i> , 2005, 280, 4825-4833.	3.4	48
128	ErbB2 Promotes Src Synthesis and Stability: Novel Mechanisms of Src Activation That Confer Breast Cancer Metastasis. <i>Cancer Research</i> , 2005, 65, 1858-1867.	0.9	264
129	A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. <i>Clinical Cancer Research</i> , 2005, 11, 217-25.	7.0	191
130	Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. <i>Clinical Cancer Research</i> , 2004, 10, 6779-6788.	7.0	293
131	Lineage Infidelity of MDA-MB-435 Cells. <i>Cancer Research</i> , 2004, 64, 3479-3485.	0.9	152
132	Liposomal Mediated Transfer of ErbB2 Antisense DNA: Coming of Age in the War Against Cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 205-206.	3.4	3
133	PI3K: Missense mutation motivates malignancy. <i>Cancer Biology and Therapy</i> , 2004, 3, 776-777.	3.4	6
134	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. <i>Cancer Cell</i> , 2004, 6, 117-127.	16.8	1,693
135	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. <i>Cancer Cell</i> , 2004, 6, 459-469.	16.8	497
136	ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2. <i>Cancer</i> , 2003, 98, 1123-1130.	4.1	45
137	Combined trastuzumab and paclitaxel treatment better inhibits ErbB2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. <i>Cancer</i> , 2003, 98, 1377-1385.	4.1	104
138	Silibinin: A Thorny Therapeutic for EGFR Expressing Tumors?. <i>Cancer Biology and Therapy</i> , 2003, 2, 532-533.	3.4	12
139	Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 Inhibits p34Cdc2 Activation and Is Involved in Resistance to Taxol-Induced Apoptosis. <i>Molecular Cell</i> , 2002, 9, 993-1004.	9.7	124
140	ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. <i>Cancer</i> , 2002, 94, 2855-2861.	4.1	118
141	Characterization of 11 human sarcoma cell strains. <i>Cancer</i> , 2002, 95, 1569-1576.	4.1	10
142	Localizing the EGF receptor - Reply. <i>Nature Cell Biology</i> , 2002, 4, E22-E23.	10.3	9
143	Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. <i>Cancer Research</i> , 2002, 62, 2034-42.	0.9	73
144	Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. <i>Cancer Research</i> , 2002, 62, 5703-10.	0.9	85

#	ARTICLE	IF	CITATIONS
145	E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. <i>Breast Cancer</i> , 2001, 8, 285-293.	2.9	20
146	Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. <i>Cancer</i> , 2001, 92, 1556-1566.	4.1	64
147	Transcriptional upregulation and activation of p53 Cdc via p34cdc2 in Taxol-induced apoptosis. <i>Oncogene</i> , 2001, 20, 2537-2543.	5.9	20
148	Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-1 in human breast cancer cells. <i>Oncogene</i> , 2001, 20, 8066-8074.	5.9	170
149	Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. , 2001, 92, 1556.		1
150	Role of erbB2 in breast cancer chemosensitivity. <i>BioEssays</i> , 2000, 22, 673-680.	2.5	106
151	Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. <i>Cancer Gene Therapy</i> , 2000, 7, 422-429.	4.6	25
152	C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. <i>Oncogene</i> , 2000, 19, 4864-4875.	5.9	106
153	Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. <i>Oncogene</i> , 2000, 19, 6115-6121.	5.9	363
154	Inhibition of the transcription factor nuclear factor- κ B by adenoviral-mediated expression of Δ B κ 1 Δ M results in tumor cell death. <i>Surgery</i> , 1999, 126, 399-405.	1.9	19
155	The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. , 1998, 17, 195-202.		27
156	The role of oncogenes in drug resistance. , 1998, 27, 283-292.		9
157	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. <i>Oncogene</i> , 1998, 16, 2087-2094.	5.9	122
158	Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase. <i>Molecular Cell</i> , 1998, 2, 581-591.	9.7	335
159	The role of oncogenes in drug resistance. , 1998, , 283-292.		1
160	Cross-reactivity of C219 Anti-p170mdr-1 Antibody With p185c-erbB2 in Breast Cancer Cells: Cautions on Evaluating p170mdr-1. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1524-1529.	6.3	39
161	Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. <i>Oncogene</i> , 1997, 14, 1965-1971.	5.9	26
162	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. <i>Oncogene</i> , 1997, 15, 953-960.	5.9	86

#	ARTICLE	IF	CITATIONS
163	HER-2/neu-targeting gene therapy-a review. <i>Gene</i> , 1995, 159, 65-71.	2.2	67
164	Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. <i>Molecular Carcinogenesis</i> , 1992, 5, 213-218.	2.7	114
165	Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 4499-4503.	7.1	142
166	Targeting the EGFR family of receptor tyrosine kinases. , 0, , 843-853.		0